Nintedanib Ratiopharm (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting fibroblast activation, angiogenesis and extracellular matrix production. This multi‑targeted inhibition reduces the fibrotic remodeling that characterises the lung diseases it treats.

The dosing regimen for Nintedanib Ratiopharm is determined by the prescribing physician based on the patient’s condition, renal and hepatic function, and tolerability. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for Nintedanib in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets a broader range of tyrosine kinases, whereas pirfenidone’s mechanism involves modulation of cytokine production and oxidative stress. Choice of therapy depends on individual patient factors, tolerability and physician judgment.

Nintedanib tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Nintedanib is taken orally, usually with food to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken at the same times each day as directed by the prescriber.

Serious risks include liver injury, severe bleeding, arterial thromboembolic events, hypertension, and gastrointestinal perforations. Patients should report any signs of jaundice, unusual bruising, severe abdominal pain, or sudden weakness to their healthcare provider promptly.

Nintedanib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, in those with active severe liver disease, and in individuals who are currently experiencing significant bleeding or have uncontrolled hypertension. Pregnant or breastfeeding women should use it only if clearly indicated by a physician.